L/N-Type Calcium Channel Blocker Cilnidipine Added to Renin-Angiotensin Inhibition Improves Ambulatory Blood Pressure Profile and Suppresses Cardiac Hypertrophy in Hypertension with Chronic Kidney Disease
Open Access
- 16 August 2013
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 14 (8), 16866-16881
- https://doi.org/10.3390/ijms140816866
Abstract
Ambulatory blood pressure (BP) and heart rate (HR) profile are proposed to be related to renal deterioration and cardiovascular complication in hypertension and chronic kidney disease (CKD). In this study, we examined the beneficial effects cilnidipine, a unique L/N-type calcium channel blocker (CCB), in addition to renin-angiotensin system inhibitors, on ambulatory BP and HR profile, as well as cardiorenal function in hypertensive CKD patients. Forty-five patients were randomly assigned to the cilnidipine replacement group (n = 21) or the control CCBs group (n = 24) during a 24-week active treatment period. Although clinical BP values were similar in the cilnidipine and control CCBs groups after the treatment period, the results of ambulatory BP monitoring showed that the 24-h and daytime systolic BP levels in the cilnidipine group were significantly lower compared with the control group after the study. Furthermore, the left ventricular mass index (LVMI) was significantly decreased in the cilnidipine group compared to the control group after the study (LVMI, 135.3 ± 26.4 versus 181.2 ± 88.4, p = 0.031), with a significant difference in the changes in the LVMI between the cilnidipine and control groups (change in LVMI, −12.4 ± 23.7 versus 26.2 ± 64.4, p = 0.007). These results indicate that cilnidipine is beneficial for the suppression of pathological cardiac remodeling, at least partly, via a superior improving effect on ambulatory BP profile compared with control CCBs in hypertensive CKD patients.This publication has 38 references indexed in Scilit:
- Antialbuminuric advantage of cilnidipine compared with L-type calcium channel blockers in type 2 diabetic patients with normoalbuminuria and microalbuminuriaDiabetes Research and Clinical Practice, 2012
- Emerging concept of anti-hypertensive therapy based on ambulatory blood pressure profile in chronic kidney disease.2011
- Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuriaHypertension Research, 2010
- Revised Equations for Estimated GFR From Serum Creatinine in JapanAmerican Journal of Kidney Diseases, 2009
- Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal diseaseKidney International, 2007
- Increased cardiac sympathetic nerve activity in heart failure is not due to desensitization of the arterial baroreflexAmerican Journal of Physiology-Heart and Circulatory Physiology, 2007
- Left ventricular mass predicted by a single reading of ambulatory blood pressure in essential hypertension.Hypertension Research, 2000
- Effects of Amlodipine and Cilnidipine on Cardiac Sympathetic Nervous System and Neurohormonal Status in Essential HypertensionHypertension, 1999
- Comparison between cilnidipine and nisoldipine with respect to effects on blood pressure and heart rate in hypertensive patients.Hypertension Research, 1998
- Relationship Between the Circadian Rhythms of Blood Pressure and Sympathovagal Balance in Diabetic Autonomic NeuropathyDiabetes, 1993